Wednesday, February 24, 2021
Home COVID 19 Updates

COVID 19 Updates

LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail

Pixel by LabCorp™ COVID-19 Test Home Collection Kit is first to receive FDA authorization for over-the-counter purchase BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global...

CPT Medical Announces Agreement with 3M, Addressing Continued PPE Shortage with N95 Mask Kits for Frontline Healthcare Workers

GREENVILLE, S.C.--(BUSINESS WIRE)--#3M--CPT Medical, a leading surgical pack and kit manufacturing firm for over 15 years, announces today their agreement with 3M to assemble...

Immunomic Therapeutics Executives and Board Members of WhyWeVax™ Discuss COVID-19 Vaccine Issues with Fox News and CDC’s ACIP Committee

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and WhyWeVax™ (WWV), a non-profit...

Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics...

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and...

If approved, the vaccine will help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia NEW YORK--(BUSINESS WIRE)--Pfizer Inc....

Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

- Financing Round Led by Viking Global Investors - - Proceeds will fund ongoing clinical development of EDG-5506, a novel, oral drug candidate for Duchenne...

 Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--$ARCT #Clinicaltrial--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious...

Seoul Viosys’ Violeds Technology for Escalator Handrail Sterilization Solutions

ANSAN, South Korea--(BUSINESS WIRE)--#AntibacterialTechnology--Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that ‘Violeds’ technology has been applied to an escalator handrail...

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease...

University of Houston McGovern College of the Arts Installs Integrated Viral Protection Biodefense Indoor Air Protection System™ to Safely Reopen Moores Opera House for...

HOUSTON--(BUSINESS WIRE)--#DrGarrettPeel--The University of Houston Kathrine G. McGovern College of the Arts has strategically partnered with Integrated Viral Protection (IVP) to re-open the Moores...

Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual...

- Viralym-M, an allogeneic, off-the-shelf, multi-virus specific T-cell therapy demonstrates 93% of patients achieved a clinical response after treatment of viral infections and disease...

Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook

Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--#clinicaltrials--Veristat, a global clinical research organization, was named among the Top Patient...

Milken Institute Future of Health Summit Opens Tomorrow, December 7

Albert Bourla, Anthony Fauci, Margaret Hamburg among 175+ speakers WASHINGTON--(BUSINESS WIRE)--The Milken Institute Future of Health Summit kicks off tomorrow, drawing more than 1,000 leaders...

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy

- Data presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting - Proof-of-concept clinical trial underway for high-risk patients with...

Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020

Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data...